A5024773466- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Renal and related cancers
- Pneumonia and Respiratory Infections
- Emergency and Acute Care Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Tuberculosis Research and Epidemiology
- RNA modifications and cancer
- Sepsis Diagnosis and Treatment
Introduction To date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to test driver alterations identify actionable therapeutic targets. In this light, comprehensive genomic profiling (CGP) with next generation sequencing (NGS) has progressively gained increasing importance in clinical practice. Here, the aim of assessing distribution and real-world frequency gene their correlation patient characteristics, we present outcomes obtained using FoundationOne (F1CDx)...
473 Background: The absence of validated prognostic and predictive biomarkers constitutes a significant barrier to appropriate selection among immune checkpoint inhibitor combinations (ICI-C) for individual patients (pts) with mccRCC. Our study aimed evaluate the value single-gene alterations (GAs) gene clusters in large real-world case series Methods: This employed data from US-based de-identified Flatiron Health-Foundation Medicine Inc. (FH-FMI) CGDB, comprising 858 mccRCC pts diagnosed...
OBJECTIVE: Merkel cell carcinoma (MCC) is a very rare and aggressive neuroendocrine skin cancer, characterized by 5-year survival rate of 13.5% in patients with distant metastases. This study aimed to evaluate the cost-utility retifanlimab compared avelumab treatment metastatic MCC who had not received prior systemic therapies, from perspective Italian National Health Service (SSN).METHODS: A 7-day cycles partitioned model three mutually exclusive health-states—progression-free,...
Background: We aimed to estimate the economic and clinical impacts of a novel diagnostic test called LIAISON® MeMed BV® (LMMBV), which can differentiate bacterial from viral infections, in patients with community-acquired pneumonia (CAP) emergency departments. Methods: A cost-impact simulation model was developed investigate financial consequences introduction LMMBV into standard care (SOC) process Italy, Germany, Spain. Clinical outcomes were expressed as antibiotic days saved, reduced...
In a randomized control trial mid-regional proadrenomedullin (MR-proADM)-guided decision-making has been proven to safely reduce hospital admissions based on an accurate assessment of disease severity in the Emergency Department (ED). This study aimed assess impact MR-proADM-Guided Triage (MR-GT) versus standard Hospital (HT) clinical and economic outcomes ED patients with suspected infection Spain, Italy, Germany, UK, using Patient-Level Data (PLD) from two observational studies.PLD was...
4553 Background: Despite a number of therapeutic improvements, mccRCC still has poor prognosis, with limited prognostic predictors for clinical practice. The aim this study was to evaluate the value three clusters co-occurring genes in mccRCC. Methods: We conducted retrospective analysis adult patients who were profiled by performing FMI genomic tests using tissue biopsies or blood samples. Data from nationwide (US-based) de-identified FH-FMI CGDB, originating approximately 280 US cancer...
4552 Background: Although the genomic landscape of mccRCC has been already documented in literature, previous clinico-genomic studies have constrained by small sample sizes, or a narrow focus on specific genes. In this large-scale study, we aimed at investigating real-world frequency and co-occurrence alterations (GAs) detected samples. Methods: This study used nationwide (US-based) de-identified FH-FMI CGDB. The data originated from approximately 280 US cancer clinics (~800 sites care)....